Renaissance Technologies’s Lucira Health, Inc. Common Stock LHDX Stock Holding History

Renaissance Technologies’s Portfolio LHDX Stock Details LHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-29,000	Closed	-$3K	–	4544
2022 Q4	$3K	Buy	+29,000	New	+$18.5K	﹤0.01%	4072
2022 Q3	–	Sell	-41,800	Closed	-$78K	–	4540
2022 Q2	$78K	Buy	+41,800	New	+$102K	﹤0.01%	3906

Other funds holding LHDX

Eclipse Ventures Palo Alto, California $2.57B AUM

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Resolute Advisors San Francisco, California $417M AUM 60.99% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Renaissance Technologies's LHDX Position: Q1 2023 in Review

Renaissance Technologies sold out of Lucira Health, Inc. Common Stock (LHDX) in Q1 2023, closing a stake of 29,000 shares — an estimated $3K sold.

Renaissance Technologies first reported a position in LHDX in Q2 2022 and held it in 2 quarters. The position peaked at $78K in Q2 2022. 6 funds tracked by Wall St. Rank hold LHDX as of Q1 2023.

Renaissance Technologies reported no remaining Lucira Health, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Renaissance Technologies sold 29,000 Lucira Health, Inc. Common Stock shares in Q1 2023, an estimated $3K.
Renaissance Technologies first reported a position in Lucira Health, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
Renaissance Technologies's Lucira Health, Inc. Common Stock position peaked at $78K in Q2 2022.
6 funds tracked by Wall St. Rank held Lucira Health, Inc. Common Stock as of Q1 2023.

Based on Renaissance Technologies's 13F filing for Q1 2023, filed 12 May 2023.